Clinical Trials for Drug: RP6530

1 Open Trials. Phone:(877.827.8839)
Protocol No. Title Status
UCI-16-45 A Phase I/Ib, Dose Escalation Study to Evaluate Safety and Efficacy of RP6530, a dual PI3K delta/gamma inhibitor, in Patients with Relapsed or Refractory T-cell Lymphoma Open